# A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age

> **NCT03303625** · PHASE1,PHASE2 · COMPLETED · sponsor: **Janssen Vaccines & Prevention B.V.** · enrollment: 48 (actual)

## Conditions studied

- Respiratory Syncytial Viruses
- Respiratory Tract Infections

## Interventions

- **BIOLOGICAL:** Ad26.RSV.preF (1*10^11 vp)
- **BIOLOGICAL:** Ad26.RSV.preF (5*10^10 vp)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03303625
- **Lead sponsor:** Janssen Vaccines & Prevention B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-29
- **Primary completion:** 2020-04-21
- **Final completion:** 2020-04-21
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03303625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03303625, "A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03303625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*